<DOC>
	<DOCNO>NCT01648023</DOCNO>
	<brief_summary>The purpose study find combination trans-arterial chemoembolization ( LC ONCOZENE BEAD ) plus infusional chemotherapy safe effective receive infusional chemotherapy alone .</brief_summary>
	<brief_title>Drug-Eluting Bead , Irinotecan Therapy Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine Cisplatin Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion : Patients 18 year age , race sex , histologic radiologic evidence intrahepatic cholangiocarcinoma , deem unresectable experienced hepatic surgeon , able give inform consent , eligible Patients least one measurable liver tumor , size &gt; 1cm ( modify RECIST criterion ) Patients liverdominant disease define ≥80 % tumor burden confine liver Nonpregnant acceptable contraception premenopausal woman . Hematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 75 x109/L , INR ≤1.3 ( patient therapeutic anticoagulant eligible stop anticoagulation prior DEBIRI meet INR criterion ) Adequate liver function measure : Total bilirubin ≤ 2.0 mg/dl , Adequate renal function ( creatinine ≤ 2.3 mg/dl ) Women child bear potential fertile men require use effective contraception ( negative serum βHCG woman childbearing age ) Signed , write informed consent Less 70 % liver parenchymal tumor replacement Exclusion : Patient eligible curative treatment ( i.e . resection tumor ablation ) . Active bacterial , viral fungal infection within 72 hour study entry Women pregnant breast feeding ECOG Performance Status score &gt; 3 Life expectancy &lt; 3 month Allergy contrast medium manage standard care ( e.g . steroid ) , make magnetic resonance imaging ( MRI ) compute tomography ( CT ) contraindicate Presence another malignancy exception cervical carcinoma situ stage I basal squamous cell carcinoma skin . Any contraindication hepatic embolization procedure : Large shunt determine investigator ( pretesting TcMMA require ) Severe atheromatosis vascular disease preclude arterial cannulization Hepatofugal blood flow Main portal vein occlusion ( e.g . thrombus tumor ) Other significant medical surgical condition , medication treatment , would place patient undue risk would preclude safe use chemoembolization would interfere study participation Patients prior contraindication use irinotecan , gemcitabine , cisplatin Patients receive prior systemic therapy either irinotecan , gemcitabine , cisplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LC Bead</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>ONCOZENE BEAD</keyword>
</DOC>